Adaptin Bio (APTN) Shares Outstanding (Weighted Average) (2022 - 2026)

Adaptin Bio has disclosed Shares Outstanding (Weighted Average) across 5 years of filings, most recently posting $2.6 million for Q1 2026.

• Quarterly Shares Outstanding (Weighted Average) fell 55.04% year-over-year to $2.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.7 million (up 49.34% YoY) and the FY2025 annual result came in at $2.6 million, down 19.82% from the prior year.
• Shares Outstanding (Weighted Average) improved to $2.6 million in Q1 2026, from $2.6 million in the prior quarter.
• Across five years, Shares Outstanding (Weighted Average) topped out at $8.5 million in Q3 2025 and bottomed at $2.6 million in Q2 2025.
• The 5-year median for Shares Outstanding (Weighted Average) is $4.1 million (2022), against an average of $4.3 million.
• Year-over-year, Shares Outstanding (Weighted Average) soared 160.18% in 2025 and sank 55.04% in 2026.
• Adaptin Bio's Shares Outstanding (Weighted Average) stood at $5.0 million in 2022, then changed by 0.0% to $5.0 million in 2023, then slumped by 35.0% to $3.2 million in 2024, then dropped by 19.82% to $2.6 million in 2025, then increased by 0.54% to $2.6 million in 2026.
• According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods registered $2.6 million, $2.6 million, and $8.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.